

Product Data Sheet

Product Name: ARN25699

Cat. No.: GC80874

Chemical Properties

Cas. No.

Formula $C_{21}H_{21}N_7O_2$

M.Wt 403.44


Solubility

Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

ARN25699 is a kinase inhibitor with an IC_{50} of 5.5 nM against GSK-3 β , 2.2 nM against FYN- α , and 242.3 nM against DYRK1A, and it exhibits oral bioavailability. ARN25699 reduces hyperphosphorylation of tau protein and promotes microtubule bundle formation. ARN25699 has a broader kinome inhibitory profile and targets kinases associated with the pathogenic mechanisms linked to Alzheimer's disease. ARN25699 can be used in the research of Alzheimer's disease and

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

related tauopathies [1].

In Vitro, ARN25699 (Compound 28) (0.1-10 μ M) inhibits a subset of kinases associated with the pathogenesis of Alzheimer's disease^[1]. ARN25699 (1-100 μ M; 6 h) induces dose-dependent microtubule bundle formation in Tau0N4R-TM-tGFP U2OS cells^[1].

References:

[1]. Demuro S, et al. A Polypharmacology-Driven Approach to Alzheimer's Disease and Tauopathies: Rational Design, Synthesis and Characterization of Amino-Pyrazole-Based Multikinase (GSK-3 β /FYN- α /DYRK1A) Inhibitors. J Med Chem. 2026 May 14;69(9):9991-10018.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA